Arcus Biosciences, Inc. (RCUS) Stock
Key stats
- Market cap
- $2.71B
- Price / Earnings ratio
- -5.9x
- EPS (TTM)
- -$3.64
- Volume
- Loading
- 52-week high
- $31.74
- 52-week low
- $17.43
Source: third-party data provider, as of November 13, 2026
Compare with RCUS
Recent news

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
RCUS

Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
RCUS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.74
- MACD 12/26/9
- -1.39
- EMA 9 of MACD
- -1.63
- MACD histogram
- 0.25
- SMA 50
- $23.11
- Price below SMA 50
- EMA 50
- $22.29
- Price below EMA 50
- SMA 200
- $24.51
- Price below SMA 200
- EMA 200
- $23.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
RCUS

Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
RCUS

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
RCUS

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
RCUS

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Arcus Biosciences, Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO | 1960 |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO | 1973 |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President | 1958 |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer | — |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Alexander Azoy CPA | Chief Accounting Officer | 1976 |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer | 1969 |
| Pia Eaves | Vice President of Investor Relations & Strategy | — |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary | 1979 |
| Holli Kolkey | Vice President of Corporate Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.74
- MACD 12/26/9
- -1.39
- EMA 9 of MACD
- -1.63
- MACD histogram
- 0.25
- SMA 50
- $23.11
- Price below SMA 50
- EMA 50
- $22.29
- Price below EMA 50
- SMA 200
- $24.51
- Price below SMA 200
- EMA 200
- $23.75
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $45.00
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +15.1 | -6.2 | ||||||||||
| 2022 | -26.4 | +18.2 | -16.0 | -24.3 | -25.2 | +31.7 | +0.3 | -3.2 | +1.7 | -2.7 | +41.1 | -40.0 |
| 2023 | +7.1 | -18.6 | +4.7 | -2.1 | +11.4 | +0.0 | -2.6 | +5.1 | -15.3 | -9.1 | -4.8 | +18.9 |
| 2024 | -23.1 | +20.7 | -1.2 | -17.6 | -2.8 | -3.9 | +7.3 | +9.0 | -7.7 | -0.8 | -0.4 | -6.6 |
| 2025 | -14.7 | -17.5 | -25.2 | +13.5 | +3.6 | -11.7 | +9.2 | +15.6 | +25.8 | +46.3 | +28.3 | -8.7 |
| 2026 | -9.7 | -6.0 | -9.8 | +16.8 | -1.3 | +20.1 | -2.5 | +6.0 | -13.1 | -27.9 | +5.3 |



